Mutagenesis within human FcepsilonRIalpha differentially affects human and murine IgE binding

Area of Science:

• Immunology
• Molecular Biology
• Allergy Research

Background:

• Soluble fragments of the high-affinity IgE receptor (FcepsilonRIalpha) show potential for treating allergic responses by competing with membrane-bound receptors.
• Understanding the specific residues involved in IgE binding to FcepsilonRIalpha is crucial for developing targeted therapies.

Purpose of the Study:

• To identify critical residues in human FcepsilonRIalpha essential for IgE binding using mutagenesis.
• To compare the binding affinities of FcepsilonRIalpha mutants to both human and mouse IgE.
• To assess the suitability of the mouse model for evaluating potential anti-allergy agents targeting human FcepsilonRIalpha.

Main Methods:

• Site-directed mutagenesis was employed to alter specific residues within the human FcepsilonRIalpha.
• The crystal structure of the FcepsilonRIalpha/IgE complex guided the selection of residues for mutagenesis.
• Binding assays were performed using purified FcepsilonRIalpha mutants and both human and mouse IgE.

Main Results:

• Mutations in the FcepsilonRIalpha2 domain (K117D, W130A, Y131A) differentially affected human IgE binding affinity.
• The K117D mutation significantly impacted mouse IgE binding, while W130A enhanced it, and Y131A had minimal effect.
• Mutations in the alpha1 domain (R15A, F17A) reduced binding to both human and mouse IgE, likely by disrupting the alpha1/alpha2 interface.

Conclusions:

• Specific residues in human FcepsilonRIalpha play distinct roles in binding human and mouse IgE.
• The mouse model may not accurately predict the efficacy of human FcepsilonRIalpha-based inhibitors in human IgE-mediated allergy.
• Findings highlight the importance of cross-species validation in allergy research and therapeutic development.